These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 33905282)
1. Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. Mba IE; Sharndama HC; Osondu-Chuka GO; Okeke OP Infect Dis (Lond); 2021 Aug; 53(8):559-580. PubMed ID: 33905282 [TBL] [Abstract][Full Text] [Related]
2. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling. Frolova EI; Palchevska O; Lukash T; Dominguez F; Britt W; Frolov I J Virol; 2022 Aug; 96(15):e0075322. PubMed ID: 35876526 [TBL] [Abstract][Full Text] [Related]
3. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19. Muralidar S; Gopal G; Visaga Ambi S J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732 [TBL] [Abstract][Full Text] [Related]
4. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818 [TBL] [Abstract][Full Text] [Related]
5. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. Li K; Meyerholz DK; Bartlett JA; McCray PB mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553 [TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651 [TBL] [Abstract][Full Text] [Related]
8. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S J Genet; 2021; 100(1):. PubMed ID: 33707363 [TBL] [Abstract][Full Text] [Related]
9. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Coronavirus Entry Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M mBio; 2020 Oct; 11(5):. PubMed ID: 33082259 [TBL] [Abstract][Full Text] [Related]
13. Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses Vishwakarma P; Yadav N; Rizvi ZA; Khan NA; Chiranjivi AK; Mani S; Bansal M; Dwivedi P; Shrivastava T; Kumar R; Awasthi A; Ahmed S; Samal S Front Immunol; 2021; 12():613045. PubMed ID: 33841395 [TBL] [Abstract][Full Text] [Related]
14. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation. Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway. Banerjee S; Wang X; Du S; Zhu C; Jia Y; Wang Y; Cai Q J Med Virol; 2022 Sep; 94(9):4071-4087. PubMed ID: 35488404 [TBL] [Abstract][Full Text] [Related]
16. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z; Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794 [TBL] [Abstract][Full Text] [Related]
17. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
18. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection. Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB Front Immunol; 2022; 13():811430. PubMed ID: 35250984 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Datta PK; Liu F; Fischer T; Rappaport J; Qin X Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005 [TBL] [Abstract][Full Text] [Related]